Abstract
Masupirdine is an oral, small, and safe molecule, readily available by a robust, two-step synthetic scheme, showing a potent, selective serotonin 5-HT(6) receptor antagonist profile, pro-cognitive effects in various behavioral animal models in Phase 3 clinical trials for the treatment of agitation in patients with Alzheimer's dementia.